Literature DB >> 26488714

Intravenous Immune Globulin for Statin-Triggered Autoimmune Myopathy.

Andrew L Mammen1, Eleni Tiniakou.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26488714      PMCID： PMC4629845          DOI： 10.1056/NEJMc1506163

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy.

Authors:  Andrew L Mammen; Tae Chung; Lisa Christopher-Stine; Paul Rosen; Antony Rosen; Kimberly R Doering; Livia A Casciola-Rosen
Journal:  Arthritis Rheum       Date:  2011-03

2.  Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy.

Authors:  Jessie L Werner; Lisa Christopher-Stine; Sharon R Ghazarian; Katherine S Pak; Jordan E Kus; Natalie R Daya; Thomas E Lloyd; Andrew L Mammen
Journal:  Arthritis Rheum       Date:  2012-12

Review 3.  Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology.

Authors:  Jordan S Orange; Elham M Hossny; Catherine R Weiler; Mark Ballow; Melvin Berger; Francisco A Bonilla; Rebecca Buckley; Javier Chinen; Yehia El-Gamal; Bruce D Mazer; Robert P Nelson; Dhavalkumar D Patel; Elizabeth Secord; Ricardo U Sorensen; Richard L Wasserman; Charlotte Cunningham-Rundles
Journal:  J Allergy Clin Immunol       Date:  2006-04       Impact factor: 10.793

4.  Immune-mediated necrotizing myopathy associated with statins.

Authors:  Phyllis Grable-Esposito; Hans D Katzberg; Steven A Greenberg; Jayashri Srinivasan; Jonathan Katz; Anthony A Amato
Journal:  Muscle Nerve       Date:  2010-02       Impact factor: 3.217

5.  Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin.

Authors:  Yves Allenbach; Laurent Drouot; Aude Rigolet; Jean Luc Charuel; Fabienne Jouen; Norma B Romero; Thierry Maisonobe; Odile Dubourg; Anthony Behin; Pascal Laforet; Tania Stojkovic; Bruno Eymard; Nathalie Costedoat-Chalumeau; Emmanuelle Campana-Salort; Anne Tournadre; Lucile Musset; Brigitte Bader-Meunier; Isabelle Kone-Paut; Jean Sibilia; Laurent Servais; Olivier Fain; Claire Larroche; Elisabeth Diot; Benjamin Terrier; Raphael De Paz; Antoine Dossier; Dominique Menard; Chafika Morati; Marielle Roux; Xavier Ferrer; Jeremie Martinet; Sophie Besnard; Remi Bellance; Patrice Cacoub; Laurent Arnaud; Bernard Grosbois; Serge Herson; Olivier Boyer; Olivier Benveniste
Journal:  Medicine (Baltimore)       Date:  2014-05       Impact factor: 1.889
  5 in total
  41 in total

Review 1.  A case of statin-associated immune-mediated necrotizing myopathy with atypical biopsy features.

Authors:  Mark M Zaki; Zain M Virk; Diego Lopez; Jenna Klubnick; Jared T Ahrendsen; Hemant Varma; Vasileios Kyttaris; Ilana Abeles
Journal:  Eur J Rheumatol       Date:  2021-01-01

Review 2.  Autoimmune Myopathies.

Authors:  Andrew L Mammen
Journal:  Continuum (Minneap Minn)       Date:  2016-12

Review 3.  Statin-Associated Muscle Adverse Events: Update for clinicians.

Authors:  Maha A Al-Mohaissen; Martha J Ignaszewski; Jiri Frohlich; Andrew P Ignaszewski
Journal:  Sultan Qaboos Univ Med J       Date:  2016-11-30

4.  Association between infection and severe drug adverse reactions: an analysis using data from the Japanese Adverse Drug Event Report database.

Authors:  Takuya Imatoh; Kimie Sai; Chisato Fukazawa; Yasushi Hinomura; Ryosuke Nakamura; Yoshimi Okamoto-Uchida; Katsunori Segawa; Yoshiro Saito
Journal:  Eur J Clin Pharmacol       Date:  2017-08-22       Impact factor: 2.953

Review 5.  Treatment in myositis.

Authors:  Chester V Oddis; Rohit Aggarwal
Journal:  Nat Rev Rheumatol       Date:  2018-03-29       Impact factor: 20.543

6.  Intravenous human immunoglobulin and/or methylprednisolone pulse therapies as a possible treat-to-target strategy in immune-mediated necrotizing myopathies.

Authors:  Jean Marcos de Souza; Leonardo Santos Hoff; Samuel Katsuyuki Shinjo
Journal:  Rheumatol Int       Date:  2019-02-18       Impact factor: 2.631

Review 7.  Novel Therapeutic Options in Treatment of Idiopathic Inflammatory Myopathies.

Authors:  Namita A Goyal; Tahseen Mozaffar
Journal:  Curr Treat Options Neurol       Date:  2018-07-23       Impact factor: 3.598

Review 8.  Potential Pathogenic Role of Anti-Signal Recognition Protein and Anti-3-hydroxy-3-methylglutaryl-CoA Reductase Antibodies in Immune-Mediated Necrotizing Myopathies.

Authors:  Leandro Ladislau; Louiza Arouche-Delaperche; Yves Allenbach; Olivier Benveniste
Journal:  Curr Rheumatol Rep       Date:  2018-08-03       Impact factor: 4.592

9.  Clinico-serologic features of statin-induced necrotising autoimmune myopathy in a single-centre cohort.

Authors:  Michael J Waters; Vidya Limaye
Journal:  Clin Rheumatol       Date:  2017-09-13       Impact factor: 2.980

10.  Absence of anti-HMG-CoA reductase autoantibodies in severe self-limited statin-related myopathy.

Authors:  James S Floyd; Jennifer A Brody; Eleni Tiniakou; Bruce M Psaty; Andrew Mammen
Journal:  Muscle Nerve       Date:  2016-06       Impact factor: 3.217
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.